Considerable knowledge has accumulated about mutations of the epidermal growth factor
receptor (EGFR)-tyrosine kinase domain since these were first identified in 2004. Patients …

Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic
kinase activity that transduces important growth factor signaling from the extracellular milieu …

Purpose EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here,
we present an update on new controversies and conclusions regarding the disease …

Despite tremendous progress in the last decade, lung adenocarcinoma still represents a
tumor with unfavorable prognosis when detected at advanced clinical stage. High-stage …

Therapy targeted against the epidermal growth factor receptor (EGFR) has demonstrated
dramatic tumor responses and favorable clinical outcomes in a select group of non-small …

The epidermal growth factor receptor (EGFR) has emerged as an attractive therapeutic
target for patients with non–small-cell lung cancer (NSCLC). However, despite its almost …

The targeting of the ATP binding pocket of the epidermal growth factor receptor (EGFR)
tyrosine kinase, by the small molecule drugs gefitinib and erlotinib, represents a promising …

Purpose It has been reported that EGFR mutations in lung carcinomas make the disease
more responsive to treatment with tyrosine kinase inhibitors. We decided to evaluate the …

Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …

Background EGFR mutant non-small cell lung cancer (NSCLC) is a heterogeneous disease.
The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the …